XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
ASSETS    
Cash and cash equivalents $ 32,428 $ 32,154
Marketable securities 21,966 37,072
Prepaid and other current assets 2,839 2,650
Total current assets 57,233 71,876
Property and equipment, net 204 296
Acquired license - intangible 281 334
Other assets 371 528
Total assets 58,089 73,034
Liabilities    
Accounts payable 1,312 2,655
Accrued liabilities 3,820 3,728
Total current liabilities 5,132 6,383
Other long-term liabilities 253 327
Total liabilities 5,385 6,710
Commitments and Contingencies (Note 14)
Stockholders' Equity    
Common stock, $0.001 par value, authorized 33,333,333 shares; issued 8,140,187 and 7,866,799 shares at September 30, 2023 and December 31, 2022, respectively; and outstanding, 8,139,449 and 7,866,061 shares at September 30, 2023 and December 31, 2022, respectively 8 8
Additional paid-in capital 576,474 574,548
Treasury stock, at cost; 738 shares at September 30, 2023 and December 31, 2022 (708) (708)
Accumulated deficit (522,716) (507,241)
Accumulated other comprehensive loss (100) (29)
Total Lisata Therapeutics, Inc. stockholders' equity 52,958 66,578
Non-controlling interests (254) (254)
Total stockholders' equity 52,704 66,324
Total liabilities, non-controlling interests and stockholders' equity $ 58,089 $ 73,034